Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
African Forests Have Become a Source of Carbon Emissions - 2From a new flagship space telescope to lunar exploration, global cooperation – and competition – will make 2026 an exciting year for space
- 341 Young Men Die in South Africa After Circumcision Initiation
- 4Find the Historical backdrop of the Modern Unrest: Changing Society and Innovation
- 5Key Training: Picking a Significant for Monetary Achievement
- Falcon 9 rocket launches Starlink satellites before making 550th SpaceX landing (video)
- Find the Standards of Viable Nurturing: Supporting Blissful and Strong Kids
- Step by step instructions to Show Children the Significance of Appropriate Handshaking
- This St Nick Truly Can Advise How To Drink And Hack Your Headache
- Can a mammogram help identify heart disease?
- These Are the Journalists Israel Has Killed Since the Start of the Iran War
- New Year's Eve Live: Nashville's Big Bash: How to watch the star-studded country music special live
- Tech for Efficiency: Applications and Apparatuses to Accomplish More
- How do my eyes adjust to the dark and how long does it take?
